Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Aquyre Biosciences
AddedFeb 15, 2024
UpdatedJun 18, 2026
Aquyre Biosciences

Aquyre Biosciences

Series A

Aquyre Biosciences provides non-invasive tissue assessment using proprietary technologies for quick, accurate results.

HQ
Boston, MA, US
Founded
2007
Overview
Compare
Fundraising
Employees
Website

Founded with the mission to revolutionize tissue assessment, Aquyre Biosciences leverages proprietary technologies to provide non-invasive, non-destructive, intraprocedural tissue adequacy assessments. Their core product combines Full-Field Optical Coherence Tomography (FFOCT) and other imaging techniques to deliver high-resolution, 3D imaging of tissue micro-architecture within two minutes. This rapid and precise assessment aids medical professionals in identifying various cell types, including cancer cells, thus enhancing biopsy sample evaluation. The company primarily focuses on the healthcare market, particularly in areas requiring quick and accurate tissue diagnostics.

Notable affiliated individuals include Dr. Wilson Tsai, Director of the Thoracic Program at John Muir Health, who supports the clinical applications of Aquyre's technology. The company has garnered attention for its significant contributions to lung biopsy procedures, becoming an industry leader in this niche. By enabling quicker and more accurate tissue assessments, Aquyre Biosciences has made a substantial impact on pathology workflows and patient outcomes, helping prioritize specimens for further examination and improving diagnostic accuracy.

Aquyre Biosciences - Quick Facts

When was Aquyre Biosciences founded?

Aquyre Biosciences was founded in 2007.

Where is Aquyre Biosciences' headquarters located?

Aquyre Biosciences' headquarters is located in Boston, MA, US.

When was Aquyre Biosciences' last funding round?

Aquyre Biosciences' most recent funding round was for $5.4M (USD) in March 2022.

How much has Aquyre Biosciences raised to-date?

As of Mar 9, 2022, Aquyre Biosciences has raised a total of $22.6M (USD).

How many employees does Aquyre Biosciences have?

Aquyre Biosciences has 40 employees as of Feb 5, 2024.

Aquyre Biosciences - Classification

Industry
  • Hardware
Ownership
  • Venture Capital
Technology
  • Biotech
  • Medical Devices
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Tissue Assessment
Tags
  • Healthcare
  • Healthtech
NAICS
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
Show 17 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 330000Manufacturing
  • 325000Chemical Manufacturing
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 325410Pharmaceutical and Medicine Manufacturing
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 3900Miscellaneous Manufacturing Industries
  • 5000Wholesale Trade-durable Goods
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 5040Professional And Commercial Equipment And Supplies
  • 8730Research, Development, And Testing Services
  • 5047Medical, Dental, And Hospital Equipment And Supplies
  • 8731Commercial Physical and Biological Research